Latest news

ClinicalJuly 14, 2026

Dysport Meets Phase 3 Goals in Episodic and Chronic Migraine Trials

Ipsen announced that its neurotoxin Dysport achieved the primary goals in two Phase 3 clinical trials evaluating the treatment...

ClinicalJuly 11, 2026

J&J Reports Positive Phase 2/3 Results for Imaavy in Warm Autoimmune Hemolytic Anemia

Johnson & Johnson has reported results from the pivotal phase 2/3 Energy study evaluating Imaavy in patients with warm...

ManufacturingJuly 11, 2026

Edgewise Reports Phase 2 CIRRUS-HCM Results for EDG-7500 Ahead of Planned Phase 3 Development

Edgewise Therapeutics has reported top-line results from Part D of the Phase 2 CIRRUS-HCM trial evaluating EDG-7500 in patients...

Research & DevelopmentJuly 11, 2026

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

The Advanced Research Projects Agency for Health (ARPA-H) has announced a new round of funding through its THRIVE program,...

InsightsJuly 10, 2026

Top 10 Barriers to Scaling Genomics Programs in Healthcare

Executive Summary Genomics is rapidly becoming a cornerstone of modern...

UncategorizedJuly 10, 2026

Xiaflex Meets Phase 3 Endpoints in Plantar Fibromatosis Study

Keenova Therapeutics reported positive phase 3 results for Xiaflex...

CommercialJuly 10, 2026

Leo Cancer Care Raises $65 Million Series D Round to Expand Upright Radiotherapy Platform

Medical technology company Leo Cancer Care has closed a $65 million Series D financing round to support the expansion...

InsightsJuly 9, 2026

The Rise of AI-Native Biotech Companies

Executive Summary Artificial intelligence is reshaping nearly every aspect of the life sciences industry. Most pharmaceutical and biotechnology companies are integrating...

InsightsJuly 9, 2026

Why Every Pharma Company Is Becoming a Technology Company

Executive Summary For much of its history, the pharmaceutical industry has been defined by scientific discovery. Competitive advantage depended on breakthrough...

CommercialJuly 9, 2026

Novartis Set to Buy UK Biotech Myricx For Over $1.1B

Novartis is expanding its presence in the antibody-drug conjugate...

ManufacturingJuly 9, 2026

Genentech signs a $490 million breast cancer partnership and lays off 103 employees with gRED Rethink

The Roche subsidiary has just announced that the restructuring...

RegulatoryJuly 9, 2026

FDA Expands Casgevy Approval to Children Aged 2 With Sickle Cell Disease and Beta Thalassemia

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Casgevy, allowing children as young as...

CommercialJuly 9, 2026

In its biggest-ever transaction, Vertex pays $10 billion to buy endocrine disease expert Crinetics

Vertex Pharmaceuticals is making its biggest-ever acquisition to date, to the tune of $10 billion, of Crinetics Pharmaceuticals. While...

ClinicalJuly 9, 2026

Phase 3 KRYSTAL-10 Study Fails to Meet Primary Endpoints for Krazati in Metastatic Colorectal Cancer

Bristol Myers Squibb has disclosed detailed results from the phase 3 KRYSTAL-10 trial evaluating Krazati (adagrasib) in combination with...

Regulatory

FDA Expands Casgevy Approval to Children Aged 2 With Sickle Cell Disease and Beta Thalassemia

The U.S. Food and Drug Administration (FDA) has expanded...

Editorial Team -

Commercial

Leo Cancer Care Raises $65 Million Series D Round to Expand Upright Radiotherapy Platform

Medical technology company Leo Cancer Care has closed a...

Editorial Team -

Commercial

Raleigh-based specialty pharma company BDSI To Be Acquired By Collegium Pharma for $604m

Collegium Pharmaceutical has its eyes on taking over all outstanding shares of BDSI for $604 million or at the rate of $5.60 per share of BioDelivery stock price.

Commercial